LIGAND PHARMACEUTICALS INCORPORATED (LGND) Operating income 2016–2025
LIGAND PHARMACEUTICALS INCORPORATED (LGND) annual operating income history from SEC filings — each fiscal year as reported.
$41.0MFY2025 · since FY2016: $43.9M → $41.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $41.0M | +281.4% |
| FY2024 | -$22.6M | -289.3% |
| FY2023 | $11.9M | +293.2% |
| FY2022 | $3.0M | -97.1% |
| FY2021 | $103.9M | +176.9% |
| FY2020 | $37.5M | -95.4% |
| FY2019 | $807.1M | +392.9% |
| FY2018 | $163.7M | +140.5% |
| FY2017 | $68.1M | +55.1% |
| FY2016 | $43.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More LGND financial trends
LGND RevenueLGND Net incomeLGND Net marginLGND Gross profitLGND Gross marginLGND Operating marginLGND Operating cash flowLGND Free cash flowLGND Capital expendituresLGND Return on equityLGND Stock buybacksLGND Dividends paidLGND Total assetsLGND Total liabilitiesLGND Shareholders’ equityLGND overview →